| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 33 | 2026 | 375 | 7.020 |
Why?
|
| Pancreatic Neoplasms | 10 | 2026 | 60 | 6.260 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2023 | 19 | 3.410 |
Why?
|
| Male | 69 | 2026 | 9556 | 2.230 |
Why?
|
| Female | 81 | 2026 | 12193 | 2.130 |
Why?
|
| Middle Aged | 62 | 2026 | 7515 | 2.080 |
Why?
|
| Humans | 94 | 2026 | 16832 | 2.070 |
Why?
|
| Delivery of Health Care, Integrated | 7 | 2026 | 515 | 1.990 |
Why?
|
| Aged | 45 | 2026 | 5901 | 1.950 |
Why?
|
| Severity of Illness Index | 13 | 2026 | 410 | 1.930 |
Why?
|
| Retrospective Studies | 39 | 2026 | 2463 | 1.930 |
Why?
|
| Dermatitis, Atopic | 2 | 2026 | 18 | 1.820 |
Why?
|
| Pancreatitis | 6 | 2026 | 54 | 1.680 |
Why?
|
| Nitric Oxide | 4 | 2019 | 10 | 1.600 |
Why?
|
| Risk Factors | 31 | 2026 | 3108 | 1.560 |
Why?
|
| Natural Language Processing | 6 | 2024 | 60 | 1.430 |
Why?
|
| Adult | 55 | 2026 | 7255 | 1.390 |
Why?
|
| Adolescent | 37 | 2024 | 3464 | 1.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2025 | 155 | 1.260 |
Why?
|
| Machine Learning | 3 | 2026 | 60 | 1.260 |
Why?
|
| Anti-Asthmatic Agents | 8 | 2019 | 85 | 1.250 |
Why?
|
| Aged, 80 and over | 15 | 2026 | 1887 | 1.240 |
Why?
|
| Young Adult | 32 | 2024 | 2456 | 1.230 |
Why?
|
| California | 28 | 2024 | 2244 | 1.120 |
Why?
|
| Child | 23 | 2026 | 2433 | 1.100 |
Why?
|
| Atrial Fibrillation | 6 | 2017 | 173 | 1.020 |
Why?
|
| Predictive Value of Tests | 13 | 2026 | 325 | 1.010 |
Why?
|
| Diabetes Mellitus | 4 | 2020 | 445 | 1.000 |
Why?
|
| Rhinitis, Allergic | 1 | 2026 | 7 | 0.950 |
Why?
|
| Stroke Volume | 2 | 2018 | 110 | 0.940 |
Why?
|
| Residence Characteristics | 3 | 2024 | 244 | 0.920 |
Why?
|
| Pancreatitis, Chronic | 2 | 2023 | 16 | 0.910 |
Why?
|
| Health Maintenance Organizations | 7 | 2016 | 358 | 0.890 |
Why?
|
| Risk Assessment | 8 | 2026 | 1047 | 0.880 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2023 | 203 | 0.880 |
Why?
|
| Atherosclerosis | 1 | 2025 | 51 | 0.860 |
Why?
|
| Crime | 1 | 2024 | 18 | 0.840 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2026 | 107 | 0.820 |
Why?
|
| Cough | 2 | 2020 | 20 | 0.810 |
Why?
|
| Adrenal Cortex Hormones | 8 | 2018 | 66 | 0.790 |
Why?
|
| Cause of Death | 3 | 2019 | 171 | 0.790 |
Why?
|
| Mortality | 2 | 2019 | 116 | 0.760 |
Why?
|
| Child, Preschool | 14 | 2026 | 1430 | 0.730 |
Why?
|
| Electronic Health Records | 7 | 2026 | 702 | 0.720 |
Why?
|
| European Continental Ancestry Group | 3 | 2020 | 400 | 0.720 |
Why?
|
| Leukoencephalopathies | 1 | 2021 | 1 | 0.690 |
Why?
|
| Brain Infarction | 1 | 2021 | 2 | 0.690 |
Why?
|
| Echocardiography | 2 | 2024 | 22 | 0.690 |
Why?
|
| Triglycerides | 2 | 2018 | 78 | 0.670 |
Why?
|
| Cohort Studies | 14 | 2024 | 2396 | 0.660 |
Why?
|
| Early Detection of Cancer | 1 | 2026 | 553 | 0.660 |
Why?
|
| Quality of Life | 4 | 2020 | 477 | 0.660 |
Why?
|
| Asian Continental Ancestry Group | 2 | 2019 | 69 | 0.640 |
Why?
|
| Pancreatic Ducts | 1 | 2020 | 5 | 0.620 |
Why?
|
| Follow-Up Studies | 10 | 2024 | 1058 | 0.620 |
Why?
|
| Gastroesophageal Reflux | 1 | 2020 | 73 | 0.600 |
Why?
|
| Glycated Hemoglobin A | 1 | 2020 | 176 | 0.590 |
Why?
|
| Propensity Score | 2 | 2018 | 78 | 0.560 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 3 | 2015 | 6 | 0.560 |
Why?
|
| Hypertriglyceridemia | 1 | 2018 | 12 | 0.560 |
Why?
|
| Hospitalization | 11 | 2026 | 816 | 0.550 |
Why?
|
| Time Factors | 11 | 2024 | 989 | 0.530 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 239 | 0.530 |
Why?
|
| Algorithms | 5 | 2024 | 210 | 0.520 |
Why?
|
| Warfarin | 4 | 2017 | 72 | 0.510 |
Why?
|
| Managed Care Programs | 7 | 2020 | 275 | 0.500 |
Why?
|
| Stroke | 5 | 2017 | 297 | 0.490 |
Why?
|
| Eosinophils | 5 | 2017 | 10 | 0.490 |
Why?
|
| Prognosis | 7 | 2020 | 568 | 0.480 |
Why?
|
| Sinusitis | 1 | 2016 | 18 | 0.480 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 174 | 0.470 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 58 | 0.460 |
Why?
|
| Prospective Studies | 6 | 2026 | 1186 | 0.450 |
Why?
|
| Incidence | 7 | 2021 | 1229 | 0.440 |
Why?
|
| Anticoagulants | 3 | 2017 | 127 | 0.440 |
Why?
|
| Continental Population Groups | 6 | 2016 | 255 | 0.440 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2016 | 158 | 0.430 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 145 | 0.430 |
Why?
|
| Breath Tests | 2 | 2011 | 5 | 0.420 |
Why?
|
| Infant, Newborn | 7 | 2025 | 828 | 0.410 |
Why?
|
| Models, Theoretical | 1 | 2014 | 66 | 0.410 |
Why?
|
| Computer Simulation | 1 | 2014 | 84 | 0.410 |
Why?
|
| Community-Institutional Relations | 1 | 2014 | 42 | 0.410 |
Why?
|
| Heart Failure | 2 | 2018 | 403 | 0.390 |
Why?
|
| Treatment Outcome | 6 | 2019 | 1098 | 0.380 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2015 | 32 | 0.380 |
Why?
|
| Models, Statistical | 1 | 2014 | 164 | 0.380 |
Why?
|
| Prevalence | 11 | 2018 | 785 | 0.380 |
Why?
|
| Disease Progression | 8 | 2024 | 252 | 0.370 |
Why?
|
| Acute Disease | 8 | 2026 | 144 | 0.370 |
Why?
|
| Biomarkers | 4 | 2019 | 284 | 0.360 |
Why?
|
| Ethnic Groups | 4 | 2010 | 418 | 0.350 |
Why?
|
| Asian Americans | 2 | 2020 | 146 | 0.340 |
Why?
|
| Emergency Service, Hospital | 6 | 2024 | 393 | 0.340 |
Why?
|
| Chronic Disease | 5 | 2020 | 382 | 0.330 |
Why?
|
| Glucocorticoids | 1 | 2010 | 22 | 0.330 |
Why?
|
| Antihypertensive Agents | 2 | 2018 | 157 | 0.320 |
Why?
|
| Kidney Failure, Chronic | 2 | 2024 | 144 | 0.310 |
Why?
|
| African Americans | 2 | 2020 | 394 | 0.300 |
Why?
|
| Quality of Health Care | 3 | 2018 | 249 | 0.300 |
Why?
|
| United States | 9 | 2022 | 3858 | 0.300 |
Why?
|
| Odds Ratio | 7 | 2019 | 569 | 0.300 |
Why?
|
| Age Factors | 7 | 2019 | 814 | 0.300 |
Why?
|
| Surveys and Questionnaires | 5 | 2020 | 1204 | 0.300 |
Why?
|
| Censuses | 2 | 2012 | 30 | 0.290 |
Why?
|
| Blood Glucose | 3 | 2024 | 315 | 0.290 |
Why?
|
| Pregnancy | 11 | 2018 | 1555 | 0.280 |
Why?
|
| Reproducibility of Results | 5 | 2026 | 346 | 0.270 |
Why?
|
| Vaccines | 2 | 2022 | 225 | 0.270 |
Why?
|
| Drug Prescriptions | 4 | 2014 | 137 | 0.270 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2018 | 42 | 0.260 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 571 | 0.260 |
Why?
|
| Intracranial Hemorrhages | 1 | 2007 | 16 | 0.260 |
Why?
|
| Pilot Projects | 2 | 2026 | 210 | 0.260 |
Why?
|
| Forced Expiratory Volume | 3 | 2012 | 59 | 0.260 |
Why?
|
| Registries | 2 | 2020 | 449 | 0.250 |
Why?
|
| Ventricular Function, Left | 2 | 2018 | 54 | 0.250 |
Why?
|
| Psychometrics | 3 | 2012 | 114 | 0.250 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2026 | 3 | 0.250 |
Why?
|
| Echocardiography, Doppler | 1 | 2026 | 3 | 0.250 |
Why?
|
| Aortic Valve | 1 | 2026 | 6 | 0.250 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2026 | 12 | 0.250 |
Why?
|
| Aortic Valve Stenosis | 1 | 2026 | 7 | 0.240 |
Why?
|
| Health Plan Implementation | 1 | 2026 | 34 | 0.240 |
Why?
|
| Myocardial Infarction | 2 | 2005 | 215 | 0.240 |
Why?
|
| Feasibility Studies | 1 | 2026 | 108 | 0.240 |
Why?
|
| Age of Onset | 1 | 2026 | 66 | 0.240 |
Why?
|
| Length of Stay | 4 | 2026 | 169 | 0.240 |
Why?
|
| Exhalation | 2 | 2019 | 2 | 0.230 |
Why?
|
| Breast Neoplasms | 4 | 2005 | 913 | 0.230 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2026 | 55 | 0.230 |
Why?
|
| Pancreas | 2 | 2023 | 14 | 0.230 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2005 | 91 | 0.220 |
Why?
|
| Hypolipidemic Agents | 1 | 2005 | 38 | 0.220 |
Why?
|
| Waiting Lists | 1 | 2024 | 11 | 0.210 |
Why?
|
| Hispanic Americans | 3 | 2020 | 350 | 0.210 |
Why?
|
| Heart Valve Diseases | 1 | 2024 | 14 | 0.210 |
Why?
|
| Recurrence | 4 | 2018 | 149 | 0.210 |
Why?
|
| Exercise Test | 1 | 2024 | 36 | 0.210 |
Why?
|
| Small-Area Analysis | 1 | 2004 | 5 | 0.210 |
Why?
|
| Kidney Transplantation | 1 | 2024 | 28 | 0.210 |
Why?
|
| Diverticulitis, Colonic | 2 | 2014 | 8 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 39 | 0.200 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 322 | 0.200 |
Why?
|
| Databases, Factual | 4 | 2019 | 294 | 0.200 |
Why?
|
| Administration, Inhalation | 3 | 2013 | 39 | 0.190 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 489 | 0.190 |
Why?
|
| Infant | 6 | 2019 | 1212 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2005 | 290 | 0.180 |
Why?
|
| Shoulder Injuries | 1 | 2022 | 2 | 0.180 |
Why?
|
| Overweight | 2 | 2015 | 262 | 0.180 |
Why?
|
| Diabetes, Gestational | 4 | 2009 | 330 | 0.170 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2011 | 5 | 0.170 |
Why?
|
| Self Report | 2 | 2020 | 248 | 0.170 |
Why?
|
| Leukocyte Count | 3 | 2017 | 23 | 0.170 |
Why?
|
| Sex Factors | 3 | 2019 | 560 | 0.160 |
Why?
|
| Comorbidity | 6 | 2017 | 516 | 0.160 |
Why?
|
| Multiple Organ Failure | 2 | 2017 | 10 | 0.160 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 104 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 48 | 0.160 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 2 | 0.160 |
Why?
|
| Data Warehousing | 1 | 2020 | 3 | 0.160 |
Why?
|
| Glycemic Index | 1 | 2020 | 17 | 0.160 |
Why?
|
| Fetal Macrosomia | 1 | 2000 | 27 | 0.160 |
Why?
|
| Anaphylaxis | 1 | 2019 | 15 | 0.150 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 24 | 0.150 |
Why?
|
| Delivery of Health Care | 3 | 2019 | 374 | 0.150 |
Why?
|
| Hypertension | 3 | 2017 | 475 | 0.150 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2017 | 23 | 0.150 |
Why?
|
| Vaccination | 2 | 2022 | 725 | 0.150 |
Why?
|
| Early Ambulation | 1 | 2019 | 4 | 0.150 |
Why?
|
| Bronchodilator Agents | 1 | 2019 | 21 | 0.140 |
Why?
|
| Eating | 1 | 2019 | 35 | 0.140 |
Why?
|
| Analgesics | 1 | 2019 | 25 | 0.140 |
Why?
|
| Pain Management | 1 | 2019 | 56 | 0.140 |
Why?
|
| Fetal Growth Retardation | 1 | 2018 | 11 | 0.140 |
Why?
|
| Disease Management | 1 | 2019 | 106 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 653 | 0.140 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2019 | 98 | 0.130 |
Why?
|
| Body Mass Index | 6 | 2020 | 925 | 0.130 |
Why?
|
| Birth Certificates | 2 | 2010 | 24 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 117 | 0.130 |
Why?
|
| Pregnancy Outcome | 3 | 2016 | 160 | 0.130 |
Why?
|
| Survival Rate | 1 | 2018 | 247 | 0.130 |
Why?
|
| Drug Utilization | 2 | 2017 | 112 | 0.130 |
Why?
|
| Febrile Neutropenia | 1 | 2017 | 3 | 0.130 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 17 | 0.130 |
Why?
|
| Research Design | 1 | 2019 | 319 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2019 | 152 | 0.130 |
Why?
|
| Insurance, Health | 1 | 2018 | 167 | 0.130 |
Why?
|
| Blood Cells | 1 | 2016 | 3 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2017 | 57 | 0.120 |
Why?
|
| Atrial Flutter | 1 | 2016 | 16 | 0.120 |
Why?
|
| Ambulatory Care | 2 | 2014 | 205 | 0.120 |
Why?
|
| Diverticulitis | 1 | 2014 | 2 | 0.110 |
Why?
|
| Eosinophilia | 1 | 2014 | 3 | 0.110 |
Why?
|
| Tamoxifen | 2 | 2005 | 52 | 0.110 |
Why?
|
| Treatment Failure | 2 | 2015 | 31 | 0.110 |
Why?
|
| Likelihood Functions | 1 | 2014 | 45 | 0.100 |
Why?
|
| Poisson Distribution | 1 | 2014 | 84 | 0.100 |
Why?
|
| Inpatients | 1 | 2014 | 78 | 0.100 |
Why?
|
| Outpatients | 1 | 2014 | 99 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 167 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2015 | 192 | 0.100 |
Why?
|
| Phenotype | 1 | 2013 | 105 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2013 | 88 | 0.100 |
Why?
|
| Health Surveys | 2 | 2011 | 226 | 0.100 |
Why?
|
| Lung | 1 | 2013 | 52 | 0.100 |
Why?
|
| Seasons | 1 | 2013 | 114 | 0.100 |
Why?
|
| Chorioamnionitis | 2 | 2010 | 18 | 0.100 |
Why?
|
| Sex Distribution | 3 | 2013 | 164 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2015 | 235 | 0.090 |
Why?
|
| Patient Selection | 2 | 2012 | 175 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2015 | 1233 | 0.090 |
Why?
|
| Rhinitis | 1 | 2012 | 2 | 0.090 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2013 | 64 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 311 | 0.090 |
Why?
|
| Age Distribution | 2 | 2013 | 221 | 0.090 |
Why?
|
| Inflammation | 1 | 2011 | 56 | 0.080 |
Why?
|
| African Continental Ancestry Group | 2 | 2012 | 117 | 0.080 |
Why?
|
| Abdominal Pain | 3 | 2017 | 13 | 0.080 |
Why?
|
| Vital Capacity | 1 | 2010 | 33 | 0.080 |
Why?
|
| International Normalized Ratio | 2 | 2008 | 21 | 0.080 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2010 | 68 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2010 | 19 | 0.080 |
Why?
|
| Logistic Models | 4 | 2017 | 796 | 0.080 |
Why?
|
| Body Height | 1 | 2010 | 54 | 0.080 |
Why?
|
| Gestational Age | 4 | 2017 | 118 | 0.080 |
Why?
|
| Health Services | 1 | 2010 | 100 | 0.080 |
Why?
|
| Glucose Intolerance | 1 | 2009 | 45 | 0.080 |
Why?
|
| Stillbirth | 1 | 2009 | 29 | 0.070 |
Why?
|
| Body Weight | 1 | 2010 | 197 | 0.070 |
Why?
|
| Postpartum Period | 1 | 2009 | 89 | 0.070 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2008 | 3 | 0.070 |
Why?
|
| Propranolol | 2 | 2018 | 4 | 0.070 |
Why?
|
| Metoprolol | 2 | 2018 | 6 | 0.070 |
Why?
|
| Atenolol | 2 | 2018 | 6 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2008 | 90 | 0.070 |
Why?
|
| Labetalol | 2 | 2018 | 9 | 0.070 |
Why?
|
| Obesity | 2 | 2013 | 811 | 0.070 |
Why?
|
| Glucose Tolerance Test | 2 | 2009 | 108 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2005 | 56 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2026 | 134 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 657 | 0.060 |
Why?
|
| Video Recording | 1 | 2026 | 18 | 0.060 |
Why?
|
| Progestins | 1 | 2005 | 24 | 0.060 |
Why?
|
| Medical Record Linkage | 1 | 2005 | 35 | 0.060 |
Why?
|
| Benzothiadiazines | 1 | 2005 | 2 | 0.060 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2005 | 7 | 0.060 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2005 | 9 | 0.060 |
Why?
|
| Health Status | 3 | 2013 | 256 | 0.060 |
Why?
|
| Paroxetine | 1 | 2005 | 12 | 0.060 |
Why?
|
| Publishing | 1 | 2005 | 9 | 0.060 |
Why?
|
| Diuretics | 1 | 2005 | 17 | 0.060 |
Why?
|
| Risk | 2 | 2017 | 453 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2005 | 191 | 0.050 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2024 | 2 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2024 | 21 | 0.050 |
Why?
|
| Public Health Informatics | 1 | 2004 | 7 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2004 | 25 | 0.050 |
Why?
|
| Geography | 1 | 2004 | 39 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2004 | 17 | 0.050 |
Why?
|
| Leukocytosis | 2 | 2014 | 5 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 140 | 0.050 |
Why?
|
| Medical Records | 1 | 2004 | 85 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 317 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 291 | 0.050 |
Why?
|
| Fever | 2 | 2014 | 52 | 0.050 |
Why?
|
| Los Angeles | 2 | 2019 | 139 | 0.050 |
Why?
|
| Drug Utilization Review | 2 | 2013 | 21 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2015 | 995 | 0.050 |
Why?
|
| Income | 2 | 2013 | 81 | 0.040 |
Why?
|
| Blindness | 1 | 2002 | 3 | 0.040 |
Why?
|
| Diabetic Retinopathy | 1 | 2002 | 17 | 0.040 |
Why?
|
| Data Collection | 2 | 2013 | 223 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 8 | 0.040 |
Why?
|
| Birth Injuries | 1 | 2000 | 1 | 0.040 |
Why?
|
| Brachial Plexus | 1 | 2000 | 1 | 0.040 |
Why?
|
| Dystocia | 1 | 2000 | 1 | 0.040 |
Why?
|
| Shoulder | 1 | 2000 | 1 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 110 | 0.040 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2000 | 6 | 0.040 |
Why?
|
| Patient Readmission | 2 | 2019 | 161 | 0.040 |
Why?
|
| Prenatal Diagnosis | 1 | 2000 | 20 | 0.040 |
Why?
|
| Obstetrics | 1 | 2000 | 20 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 93 | 0.040 |
Why?
|
| Fasting | 1 | 1999 | 45 | 0.040 |
Why?
|
| Food | 1 | 1999 | 36 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 520 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 1999 | 4 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2019 | 25 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 138 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 103 | 0.040 |
Why?
|
| Patient Transfer | 1 | 1999 | 25 | 0.040 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2018 | 55 | 0.030 |
Why?
|
| Smoking | 1 | 2020 | 373 | 0.030 |
Why?
|
| Critical Care | 1 | 1999 | 62 | 0.030 |
Why?
|
| Whooping Cough | 1 | 2019 | 71 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 9 | 0.030 |
Why?
|
| Eclampsia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 23 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2017 | 30 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 43 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2017 | 41 | 0.030 |
Why?
|
| Cell Count | 1 | 2016 | 9 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2017 | 62 | 0.030 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 27 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 41 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 84 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 202 | 0.030 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2015 | 199 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 120 | 0.020 |
Why?
|
| Health Resources | 1 | 2013 | 35 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 129 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2013 | 58 | 0.020 |
Why?
|
| Pharmaceutical Services | 1 | 2013 | 37 | 0.020 |
Why?
|
| Abscess | 1 | 2012 | 5 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 201 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 261 | 0.020 |
Why?
|
| Process Assessment (Health Care) | 1 | 2012 | 22 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2012 | 69 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 163 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 114 | 0.020 |
Why?
|
| Health Services Research | 1 | 2012 | 180 | 0.020 |
Why?
|
| Health Planning | 1 | 2010 | 15 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 37 | 0.020 |
Why?
|
| Poverty | 1 | 2012 | 167 | 0.020 |
Why?
|
| Catchment Area (Health) | 1 | 2010 | 8 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 207 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 2010 | 8 | 0.020 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2010 | 12 | 0.020 |
Why?
|
| Maternal Age | 1 | 2010 | 73 | 0.020 |
Why?
|
| Fetal Distress | 1 | 2009 | 4 | 0.020 |
Why?
|
| Conjunctivitis | 1 | 2008 | 2 | 0.020 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2008 | 8 | 0.020 |
Why?
|
| Otitis Media | 1 | 2008 | 19 | 0.020 |
Why?
|
| Fatigue | 1 | 2008 | 30 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 213 | 0.020 |
Why?
|
| Models, Economic | 1 | 2008 | 16 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 13 | 0.020 |
Why?
|
| Group Practice | 1 | 2008 | 20 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 66 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2005 | 4 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 79 | 0.010 |
Why?
|
| Estrogen Antagonists | 1 | 2004 | 2 | 0.010 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2004 | 10 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2003 | 25 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 68 | 0.010 |
Why?
|
| Vitrectomy | 1 | 2002 | 1 | 0.010 |
Why?
|
| Laser Coagulation | 1 | 2002 | 1 | 0.010 |
Why?
|
| Visual Acuity | 1 | 2002 | 5 | 0.010 |
Why?
|
| Prenatal Care | 1 | 2003 | 123 | 0.010 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 1999 | 1 | 0.010 |
Why?
|
| Kinetics | 1 | 1999 | 12 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1999 | 12 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1999 | 17 | 0.010 |
Why?
|
| Diagnosis-Related Groups | 1 | 1999 | 18 | 0.010 |
Why?
|
| Insulin | 1 | 1999 | 181 | 0.010 |
Why?
|
| Mass Screening | 1 | 2003 | 670 | 0.010 |
Why?
|